Posts by tag
pancreatic ductal adenocarcinoma
When RAS Becomes Treatable: Eileen O’Reilly on daraxonrasib in Pancreatic Cancer
Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…
Daraxonrasib: A Turning Point for Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…
MRI technique can identify pre-malignant pancreatic lesions
Diffusion tensor imaging (DTI), a form of MRI, is capable of detecting pre-malignant lesions in both mouse and human pancreatic specimens. The ‘proof of concept’ study, published in Investigative Radiology, 13 December 2024, opens the way to use DTI for…
New drug breaks through fibrotic tissue in pancreatic cancer
A drug targeting scar-like ‘fibrotic’ tissue within tumours shows promise for treating pancreatic ductal adenocarcinoma (PDAC). In the study, reported online in Nature Cancer, 28 August, Australian investigators showed in mouse and human models of PDAC that, when the drug…